Page 13 - Genmark Diagnostics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Extended Stay America, Inc. (NASDAQ: STAY)  WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Extended Stay America, Inc. (NASDAQ: STAY) in connection with the proposed acquisition of the company and its paired-share REIT, ESH Hospitality, Inc., by funds managed by Blackstone Real Estate Partners and Starwood Capital Group. Under the terms of the merger agreement, STAY shareholders will receive $19.50 in cash for each share of STAY common stock that they hold. If you own STAY shares and wish to discuss this investiga...

3 Min Read MILAN (Reuters) -Shares in DiaSorin jumped as much as 10% on Monday after the Italian diagnostics group said it was buying U.S. rival Luminex Corp in a $1.8 billion all-cash deal that strengthens its molecular business. The global coronavirus pandemic has fuelled rapid growth at the company’s molecular division, which accounted for 29% of 2020 sales. The Luminex acquisition consolidates DiaSorin’s presence in the U.S. market and strengthens its position in molecular diagnostics to help offset an expected drop in demand for COVID-19 molecular tests as the vaccine rollout progres...

UPDATE 1-Shares in Italy's DiaSorin jump after $1.8 bln Luminex acquisition Reuters 1 hr ago By Giancarlo Navach MILAN, April 12 (Reuters) - Shares in DiaSorin jumped as much as 10% on Monday after the Italian diagnostics group said it was buying U.S. rival Luminex Corp in a $1.8 billion all-cash deal that strengthens its molecular business. The global coronavirus pandemic has fuelled rapid growth at the company's molecular division, which accounted for 29% of 2020 sales. The Luminex acquisition consolidates DiaSorin's presence in the U.S. market and strengthens its position in molecular di...

Italian diagnostics firm DiaSorin has agreed to buy U.S. rival Luminex Corp for $1.8 billion in a move that could boost its molecular business and offset a potential drop in demand for COVID-19 tests as the pandemic is brought under control.

MedTech industry news